Philippines secures $250 million loan from ADB for COVID-19 vaccines
Reuters
Published Dec 13, 2021 02:30AM ET
Updated Dec 13, 2021 03:30AM ET
MANILA (Reuters) - The Asian Development Bank (ADB) has approved a $250 million loan for the Philippines to purchase COVID-19 vaccines, it said in a statement on Monday.
The ADB said the loan would allow the government to purchase 40 million additional COVID-19 vaccine doses for eligible children and booster shots for adults.
The Philippines is aiming to fully vaccinate at least 54 million people, or nearly half of its 110 million population, before the year ends.
To reach that target, it plans to hold a second three-day mass vaccination campaign from Dec. 15. It has so far fully immunised 39.2 million as of Dec. 7.
New daily cases in the Philippines have stayed below 1,000 since Nov. 24, a sharp decline from the more than 20,000 peak in late September that strained the fragile health system in the Southeast Asian archipelago.
The Philippines' improving COVID-19 situation has allowed it to gradually reopen the economy and tentatively resume in-person classes.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.